[1] RAM P, SHAH M, SIRINVARAVONG N, et al. Left ventricular thrombosis in acute anterior myocardial infarction: evaluation of hospital mortality, thromboembolism, and bleeding[J]. Clin Cardiol, 2018, 41(10): 1289. doi: 10.1002/clc.23039
[2] ROE A, BANKA P, MOONEY M. No time to delay reperfusion: a cross-sectional study of primary percutaneous coronary intervention times[J]. J Clin Nurs, 2019, 28(17/18): 3233.
[3] 韦锋. 重组人脑利钠肽对STEMI并发心力衰竭不同靶血管病变行急诊PCI术后的治疗效果分析[J]. 蚌埠医学院学报, 2020, 45(2): 232.
[4] ANDERSON JL, MORROW DA. Acute myocardial infarction[J]. N Engl J Med, 2017, 376(21): 2053. doi: 10.1056/NEJMra1606915
[5] 张倩, 刘宣宣, 张文琪. 急性前壁心肌梗死后左心室血栓形成的研究进展[J]. 中国循证心血管医学杂志, 2020, 12(12): 1540. doi: 10.3969/j.issn.1674-4055.2020.12.33
[6] MCCARTHY CP, VADUGANATHAN M, et al. Left ventricular thrombus after acute myocardial infarction: screening, prevention, and treatment[J]. JAMA Cardiol, 2018, 3(7): 642. doi: 10.1001/jamacardio.2018.1086
[7] 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病志, 2019, 47(10): 766.
[8] 王晓黎, 李志, 徐晤. 静脉应用肾上腺素对经皮冠状动脉介入治疗术中无复流的影响[J]. 徐州医科大学学报, 2022, 42(6): 446. doi: 10.3969/j.issn.2096-3882.2022.06.011
[9] KALARUS Z, SVENDSEN JH, CAPODANNO D, et al. Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association(EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions(EAPCI), and European Acute Cardiovascular Care Association(ACCA)[J]. Europace, 2019, 21(10): 1603. doi: 10.1093/europace/euz163
[10] KARIO K. The sacubitril/valsartan, a first-in-class, angiotensin receptor neprilysin inhibitor(ARNI): potential uses in hypertension, heart failure, and beyond[J]. Curr Cardiol Rep, 2018, 20(1): 5. doi: 10.1007/s11886-018-0944-4
[11] SAUER AJ, COLE R, JENSEN BC, et al. Practical guidance on the use of sacubitril/valsartan for heart failure[J]. Heart Fail Rev, 2019, 24(2): 167. doi: 10.1007/s10741-018-9757-1
[12] DRAZNER MH. Angiotensin Receptor-Neprilysin Inhibition(ARNI) therapy and reverse remodeling in heart failure with reduced ejection fraction[J]. JAMA, 2019, 322(11): 1051. doi: 10.1001/jama.2019.12662
[13] ROSSIGNOL P, HERNANDEZ AF, SOLOMON SD, et al. Heart failure drug treatment[J]. Lancet, 2019, 393(10175): 1034. doi: 10.1016/S0140-6736(18)31808-7
[14] KHDER Y, SHI V, MCMURRAY JJV, et al. Sacubitril/Valsartan(LCZ696) in heart failure[J]. Handb Exp Pharmacol, 2017, 243: 133.
[15] TORRADO J, CAIN C, MAURO AG, et al. Sacubitril/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits[J]. J Am Coll Cardiol, 2018, 72(19): 2342. doi: 10.1016/j.jacc.2018.07.102
[16] DESAI AS, SOLOMON SD, SHAH AM, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial[J]. JAMA, 2019, 322(11): 1077. doi: 10.1001/jama.2019.12843